Whether the premium vaccine market, which consists of vaccines used to prevent diseases like shingles, pneumococcal vaccines, etc., will be able to overcome the COVID-19 crisis and make a rebound is gaining attention.

Expectations of market recovery are rising in the pharma and bio-industry with the eased resurgence of COVID-19, cautious expectations on the nearing end of the COVID-19 pandemic, and potential new product releases being in the two vaccine areas.

◆Shingrix expected to be released at the end of the year...Will the contracted market rebound after COVID-19

According to industry sources on the 8th, GSK and GC Pharma plan to jointly promote the sales of the new